



## Widespread hyperpigmented rash present for 1 year

Carly Dunn, BA, Danielle S. Applebaum, MD, and Harry Dao, Jr, MD  
*Houston, Texas*

**Key words:** erythrasma; general dermatology; medical dermatology.



A 59-year-old woman with type II diabetes mellitus and obesity presented to the clinic for evaluation of a hyperpigmented rash located in her axillae, groin, buttock, umbilicus, and inframammary region (Figs 1 to 6) of 1 years' duration. She reported pruritus and occasional fissuring after scratching. She was treated previously with nystatin powder, clotrimazole cream, and oral fluconazole for 4 weeks with minimal improvement.

---

From Baylor College of Medicine.

Funding sources: None.

Conflicts of interest: None disclosed.

Correspondence to: Harry Dao, Jr, MD, 1977 Butler Blvd, Suite E6.200, Houston, TX 77030. E-mail: [harry.daojr@bcm.edu](mailto:harry.daojr@bcm.edu).


JAAD Case Reports 2018;4:743-5.

---

2352-5126

© 2018 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<https://doi.org/10.1016/j.jdcr.2018.04.012>

**Question 1: What is the diagnosis?**

- A. Mycosis fungoides
- B. Inverse psoriasis
- C. Dermatophytosis
- D. Erythrasma
- E. Candidiasis

**Answers:**

- A. Mycosis fungoides — Incorrect. Mycosis fungoides classically appears as patches. It takes years to develop and most cases occur in whites (70%; Hispanics, 9%).<sup>1</sup>
- B. Inverse psoriasis — Incorrect. Inverse psoriasis presents with erythematous, shiny, moist plaques in intertriginous areas but with no scale.<sup>2,3</sup>
- C. Dermatophytosis — Incorrect. Dermatophytosis often occurs with onychomycosis; lack of response to antifungals makes this diagnosis less likely.<sup>4</sup>
- D. Erythrasma — Correct. Erythrasma presents with erythematous to tan, asymptomatic or pruritic scaly plaques in intertriginous areas and is caused

by *Corynebacterium minutissimum*.<sup>5,6</sup> Risk factors include obesity, poor hygiene, warm climate, and diabetes mellitus.<sup>7</sup>

- E. Candidiasis — Incorrect. Candidiasis has satellite papules and would have improved with antifungals.

**Question 2: What does Wood's lamp detect in this patient?**

- A. Coproporphyrin III
- B. Melanin
- C. Rhodopsin
- D. Carotenoid
- E. Pyocyanin

**Answers:**

- A. Coproporphyrin III — Correct. Diagnosis of erythrasma can be made easily by Wood's lamp examination, which characteristically fluoresces coral red due to coproporphyrin III.<sup>5,8</sup>
- B. Melanin — Incorrect. Wood's lamp does not detect melanin, the naturally occurring pigment in skin and hair.

- C.** Rhodopsin — Incorrect. Wood's lamp does not detect rhodopsin, which is the purple pigment in eyes that helps with sight in dim light.
- D.** Carotenoid — Incorrect. Wood's lamp does not detect these red, yellow, or orange pigments, such as carotene, which give color to plant parts such as carrots or fall leaves.
- E.** Pyocyanin — Incorrect. Wood's lamp does not detect this blue-green pigment, which gives *Pseudomonas* its characteristic color.

**Question 3: How would you treat this patient?**

- A.** Topical steroids
- B.** Macrolide antibiotic
- C.** Immunotherapy
- D.** Topical antifungals
- E.** Barrier cream

**Answers:**

- A.** Topical steroids — Incorrect. Topical steroids would be used for a diagnosis of inverse psoriasis and are not indicated for erythrasma, as it is a bacterial infection.<sup>2</sup>
- B.** Macrolide antibiotic — Correct. Erythrasma is treated with topical clindamycin, erythromycin, or antibacterial soaps, such as benzoyl peroxide.<sup>7</sup> For recalcitrant or extensive disease, a 5- to 14-day course of oral erythromycin or clarithromycin is used to eliminate the *Corynebacterium*. For therapeutic failure of intertriginous involvement, topical clindamycin or other antibacterial soaps are added.
- C.** Immunotherapy — Incorrect. Immunotherapy can be used for cutaneous malignancies, such as mycosis fungoides; however, immunotherapy is not used for the treatment of erythrasma.<sup>1</sup>

**D.** Topical antifungals — Incorrect. The patient has not responded to topical and oral antifungals, and these are not indicated in the treatment of erythrasma.

**E.** Barrier cream — Incorrect. Barrier creams are typically used to treat dermatitis and dry skin and work to improve barrier function of the skin and reduce its susceptibility to irritants.<sup>9</sup>

**DISCUSSION**

This article represents an interesting presentation of extensive erythrasma, which required a biopsy for diagnosis. This case highlights the importance of keeping erythrasma on the differential diagnosis of a rash in the intertriginous areas, especially as it can be easily identified with Wood's Lamp in the office.

**REFERENCES**

1. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): Part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. *J Am Acad Dermatol*. 2014;70(2):205-e1-e16.
2. Syed Z, Khachemoune A. Inverse psoriasis: case presentation and review. *Am J Clin Dermatol*. 2011;12(2):143-146.
3. Omland SH, Gniadecki R. Psoriasis inversa: a separate identity or a variant of psoriasis vulgaris? *Clin Dermatol*. 2015;33(4):456-461.
4. Pires CAA, da Cruz NFS, Lobato AM, de Sousa PO, Carneiro FRO, Mendes AMD. Clinical, epidemiological, and therapeutic profile of dermatophytosis. *An Bras Dermatol*. 2014;89(2):259-264.
5. Wilson BB, Wagenseller A, Noland MMB. An atypical presentation of erythrasma. *J Am Acad Dermatol*. 2012;67(5):e217-e218.
6. Sarkany I, Taplin D, Blank H. The etiology and treatment of erythrasma. *J Invest Dermatol*. 1961;37(4):283-290.
7. Holdiness MR. Management of cutaneous erythrasma. *Drugs*. 2002;62(8):1131-1141.
8. Yasuma A, Ochiai T, Azuma M, et al. Exogenous coproporphyrin III production by *Corynebacterium aurimucosum* and *Microbacterium oxydans* in erythrasma lesions. *J Med Microbiol*. 2011;60(7):1038-1042.
9. Lodén M, Andersson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm®). *Br J Dermatol*. 1999;140(2):264-267.